Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Philip L. McCarthy et al.|New England Journal of Medicine|2022Cited by 457
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J. Costa, Parameswaran Hari, Yi Lin et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 45